Literature DB >> 21557640

Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond.

Maurizio Chiriva-Internati1.   

Abstract

Sperm protein 17 belongs to the cancer/testis antigen family and was found to play a key role in the cell fusion process between the mammalian spermatozoa and egg. Sperm protein 17-specific autoantibodies in vasectomized males suggest its high expression in the testis. Sperm protein 17 expression levels are low or absent in normal tissues, other than the testis. Sperm protein 17 is expressed by tumors, including ovarian cancer, indicating that it is an ideal target for cancer immunotherapy, and plays a role in tumorigenesis and drug resistance. This review recapitulates the milestones of sperm protein 17 research and highlights its potential use in translational medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21557640     DOI: 10.3109/08830185.2011.569903

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  5 in total

1.  Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.

Authors:  Jia-xi Song; Wang-li Cao; Fang-qiu Li; Li-ning Shi; Xuan Jia
Journal:  Med Oncol       Date:  2011-12-24       Impact factor: 3.064

2.  Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.

Authors:  Zewei Tu; Jie Peng; Xiaoyan Long; Jingying Li; Lei Wu; Kai Huang; Xingen Zhu
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

3.  Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.

Authors:  Leonardo Mirandola; Elisa Pedretti; Jose A Figueroa; Raffaella Chiaramonte; Michela Colombo; Caroline Chapman; Fabio Grizzi; Federica Patrinicola; W Martin Kast; Diane D Nguyen; Rakhshanda Layeequr Rahman; Naval Daver; Peter Ruvolo; Sean M Post; Robert S Bresalier; Maurizio Chiriva-Internati
Journal:  Oncotarget       Date:  2017-08-10

4.  Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses.

Authors:  Sue D Xiang; Kirsty L Wilson; Anne Goubier; Arne Heyerick; Magdalena Plebanski
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

5.  Rethinking immunotherapy for brain cancers in the light of cancer complexity.

Authors:  Fabio Grizzi; Antonio Di Ieva
Journal:  Indian J Med Res       Date:  2013-05       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.